See our digital tools showcase

Oncology · Program readiness check

Which TrialBlazer reforms touch your oncology program?

Operation TrialBlazer reads like an oncology reform. Set your program below to see which items apply to you, and where each one stands.

None of these are final FDA guidance yet — here’s where each stands:

  • Draft — FDA’s current thinking, open for comment; not binding and subject to change.
  • Revised draft — an update to earlier guidance, still in draft.
  • Signaled, not yet issued — named in the roadmap; no specific FDA guidance exists.
Readiness self-check

Set your program

Modality
Development context select any that apply
Program stage
Your readiness read

Choose your modality to see which of the four TrialBlazer items touch your program. Add your development context and stage to sharpen the read.

Why it matters

Operation TrialBlazer is written as a broad, department-wide HHS effort to speed early research. Read it closely and much of the concrete material lands on oncology — the one therapy-area nonclinical guidance is for oncology products, the trial-design reforms target designs oncology pioneered, and the modalities singled out for flexibility are, disproportionately, cancer modalities.

Trial access, one figure

Each square is one cancer patient. One reaches a trial.

<1 in 20
treated in a trial
cancer patients are treated within a clinical trial, by figures cited in the roadmap, even though most say they would take part if asked. Closing that gap is the point of moving faster.

Figure as cited in the HHS Operation TrialBlazer roadmap. Verify against primary source before external use.

The programs that benefit are the ones that treat TrialBlazer as specific and actionable, not as generic regulatory news to file away.

The four reforms, in full

The detail behind the calculator. The items your selection flags are highlighted.

1
Streamlined nonclinical safety — biologics & conjugated products.

A draft guidance aimed squarely at antibody-drug conjugates and oncology biologics, moving toward a risk-based, weight-of-evidence approach that can reduce certain animal studies. Issued as a draft, pending finalization.

Draft · May 2026ADC & biologics
2
Revised master-protocols guidance.

A revised draft on master-protocol design — and, notably, FDA’s original master-protocol guidance was itself oncology-specific. Relevant to anyone running or planning a basket, umbrella, or platform study.

Revised draftBasket / umbrella / platform
3
Revised “substantial evidence” guidance.

A revised draft on when one adequate and well-controlled study plus confirmatory evidence can support approval, rather than two. It is the substantial-evidence standard — related to, but distinct from, the accelerated-approval pathway — and it shapes the evidence case many single-arm oncology programs build.

Revised draftEvidence standard
4
Flexibility for radioligand therapy.

Operation TrialBlazer names no radiopharma-specific rule. But its nonclinical, trial-design, and evidence directions all reach radioligand therapy — where imaging-based selection and dosimetry, not the molecule alone, often decide eligibility and dose. Our imaging principal has written on what that raises for imaging endpoints.

SignaledRadiopharma / theranostics

What has landed, and what has not

None of the oncology-relevant guidances are final. The roadmap’s headline items, namely the Expedited-IND pilot and the single-IRB proposal, remain out for comment.

Draft guidance · informs planning now
  • Streamlined nonclinical safety — biologics & conjugated products (ADCs)
  • Revised master-protocols guidance
  • Revised “substantial evidence” guidance
Proposed · out for comment
  • Expedited-IND pilot
  • Single-IRB proposal

Questions sponsors are asking

What is Operation TrialBlazer? +
A department-wide HHS effort, launched in June 2026, to speed and modernize early clinical research in the United States. Much of its concrete material is delivered through FDA draft guidances, several of which land on oncology.
Which parts of TrialBlazer apply to oncology? +
Three draft FDA guidances are most relevant: streamlined nonclinical safety studies for biologics and conjugated products (ADCs), revised master-protocols guidance, and a revised standard for demonstrating substantial evidence of effectiveness. The roadmap also signals added flexibility for advanced modalities such as radioligand therapy.
What is in force now versus still proposed? +
None of the oncology-relevant guidances are final. All three are drafts, which can inform planning now but are not settled. The roadmap’s headline items — an expedited-IND pilot and a single-IRB proposal — remain out for comment.
What does it change for ADCs and oncology biologics? +
A May 2026 draft guidance moves toward a risk-based, weight-of-evidence approach that can reduce certain animal studies for ADCs and oncology biologics. It is a draft, pending finalization.
What does it mean for radioligand therapy? +
There is no radiopharma-specific rule. The roadmap’s direction on nonclinical expectations, trial design, and evidence standards reaches advanced modalities including radioligand therapy, where imaging endpoints and dosimetry often decide eligibility. That intersection of the reforms and imaging strategy is where readiness is won or lost.
What is a TrialBlazer readiness read? +
A focused read from The Bracken Group on one of your oncology programs: which reforms touch your development plan, which early studies you could reasonably reconsider, and where the line sits between acting now and waiting. Specific to your program, no obligation.

Guidance statuses reflect FDA draft and revised-draft status as of July 2026; figures are cited to the HHS Operation TrialBlazer roadmap. This tool is a general orientation for oncology sponsors, not regulatory advice.